Key result
PRKCB immunohistochemistry detects EWSR1 rearranged Ewing sarcoma with ~98% sensitivity.
Why the study?
To investigate whether PRKCB immunohistochemistry is a surrogate marker for diagnosing Ewing sarcoma in routine practice.
Does PRKCB immunohistochemistry accurately diagnose Ewing sarcoma compared to molecular methods?
Cross-Sectional (n=110)
Does PRKCB immunohistochemistry accurately diagnose Ewing sarcoma compared to molecular methods?
PRKCB immunohistochemistry is a highly sensitive and specific surrogate marker for diagnosing Ewing sarcoma in routine practice.
PRKCB IHC may support EWSR1 surrogate testing in Ewing sarcoma; leaves open prospective validation before routine adoption.
Background: Ewing sarcoma (ES) can be confirmed by identifying the EWSR1-FLI1 fusion transcript. This study is to investigate whether immunostaining (IHC) of PRKCB—a protein directly regulated by EWSR1-FLI1 is a surrogate maker for diagnosing ES in routine practice. Methods: Microarray gene expression analyses were conducted. RKCB IHC was applied to 69 ES confirmed by morphology and molecular methods, and 41 non-Ewing small round cell tumors. EWSR1 rearrangement, EWSR1-FLI1 fusion or t(11;22)(q24;q12) were identified by fluorescence in situ hybridization, reverse transcriptase polymerase chain reaction, or cytogenetic analysis, respectively. Results: Gene array analyses showed significant overexpression of the PRKCB in ES. PRKCB IHC was positive in 19 cases of ES with EWSR1-FLI1 fusion, 3 cases with cytogenetic 11:22 translocation and 59 cases with EWSR1 rearrangement while negative in only one EWSR1 rearranged case. PRKCB IHC is sensitive (98%) and specific (96%) in detecting EWSR1 rearranged ES. Conclusions: PRKCB is a reliable antibody for diagnosing ES in routine practice.
No takes yet. Share an insight, caveat, or question.
Zota et al. (2022) conducted a cross-sectional in Ewing sarcoma (n=110). PRKCB immunohistochemistry vs. Molecular methods was evaluated on Detection of EWSR1 rearranged Ewing sarcoma (Sensitivity 98%, Specificity 96%). PRKCB immunohistochemistry demonstrated 98% sensitivity and 96% specificity in detecting EWSR1 rearranged Ewing sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: